SAN DIEGO, May 17, 2016 /PRNewswire/ -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed a testing platform designed specifically for point-of-care infectious disease diagnosis, today announced the appointment of Tom Willardson as Chief Financial Officer and John Monroe as Senior Vice President of Operations.
"We are delighted to have Tom and John join the Mesa Biotech team," said Hong Cai, co-founder and CEO of Mesa Biotech. "Tom has a proven track record with both venture-backed and public companies and will provide the leadership, strategic vision and financing expertise required to maximize the company's financial health. John has a wealth of experience establishing manufacturing processes from start-up through high volume manufacturing and will be instrumental in establishing our manufacturing scale-up strategy and ensuring we meet our quality, productivity and efficiency goals."
Willardson is an experienced CFO with more than 30 years of diverse industry experience in both large global companies and early stage start-ups. He has successfully raised over $300 million in public and private equity and debt. Willardson received his B.S. degree in Finance from Brigham Young University and an MBA in Finance from the University of Southern California.
Monroe brings extensive operational and manufacturing expertise to Mesa Biotech. He has more than 20 years of lateral flow manufacturing experience at Quidel and Alere. Most recently in his role as Director of Operations and R&D at Alere, Monroe led the startup operations team and was responsible for oversight of the OEM manufacturing partners for bulk solutions, product fills and packaging. He received his B.S. degree in biology from San Diego State University.
About Mesa Biotech Inc.
Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech's diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa's technology development has been funded to date by a series of grants and private equity investments totaling approximately $30 million. The company is preparing for Series A funding in 2016 and expects to obtain FDA approval for its first product, an influenza assay and dock, in 2017. For more information visit http://www.mesabiotech.com.
SOURCE Mesa Biotech Inc.